Document is current
Any future updates will be listed below
-
Authors
Sweerts, Kim W. E.
Vork, Lisa https://orcid.org/0000-0001-7316-3191
Mujagic, Zlatan https://orcid.org/0000-0001-5211-0381
Conchillo, José M. https://orcid.org/0000-0003-0958-4164
Keszthelyi, Daniel https://orcid.org/0000-0001-9856-9980
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 20 June 2025
First Online: 26 July 2025
Declarations
:
: K.W.E. Sweerts: nothing to declare. The authors declare no competing interests. L. Vork: nothing to declare. Z. Mujagic: Research grants form MLDS, ZonMw, Niels Stensen Fellowship, Galapagos, TKI. Advisory board fees: Johnson & Johnson, Eli Lilly, Pfizer, Abbvie (paid to host institution). Speaker’s fee: Galapagos, Eli Lilly, Takeda (paid to host institution). None related to the current study. J.M. Conchillo: nothing to declare. D. Keszthelyi: Research grants from MLDS, Rome Foundation, ZonMw, Rome Foundation, UEG, Horizon Europe, no conflict of interest regarding this manuscript.
: The study protocol was approved by the MUMC + Committee of Ethics in July 2016, and all study procedures were executed in compliance with Good Clinical Practice Guidelines and according to the revised Declaration of Helsinki.
